Publications by authors named "John Emswiler"
Am J Transplant
March 2005
Article Synopsis
- Current organ transplantation success relies on calcineurin-inhibitor immunosuppressive regimens, but these often cause severe side effects due to targeting widely expressed molecules.
- T-cell costimulation, particularly the CD28/CTLA4 pathway and its ligands CD80/CD86, offers a new immunosuppressive target, although earlier CTLA4 fusion proteins showed limited success in primate models.
- A modified CTLA4-Ig called LEA29Y (belatacept) was developed with two amino acid changes, increasing its potency significantly in vitro and improving renal transplant survival in pre-clinical studies, suggesting that targeted immunotherapy may reduce harmful side effects of standard treatments.
